| Document |
Document Title |
|
WO/2022/236118A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 ...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/229315A1 |
Provided are novel compounds for use as inhibitors of NLRP3 inflammasomeproduction, wherein such compounds are as defined by compounds of formula (I) wherein R1, R2 and R3a and R3b are as defined in the description, and where thecompound...
|
|
WO/2022/229055A1 |
The present invention relates to substituted pyridazinones of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their use as h...
|
|
WO/2022/219634A1 |
The present invention is directed to a composition comprising a polymer comprising a first hyaluronic acid (HA) chain and a second HA chain crosslinked via a linker comprising an unsaturated moiety or a derivative thereof coupled to a te...
|
|
WO/2022/217239A1 |
Disclosed herein are compounds which inhibit PU.1, pharmaceutical formulations, and methods of treatment of PU.1-mediated diseases, such as Alzheimer's disease, inflammation, and diseases related to excessive myelin uptake.
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/206705A1 |
The present invention provides a heterocyclic compound as a TYK2 pseudokinase (JH2) domain inhibitor, a synthetic method, and use. In particular, the present invention provides a heterocyclic compound as represented by formula I, or a ph...
|
|
WO/2022/194073A1 |
Disclosed in the present invention are a salt form and a crystal form of a 1,2,4-triazine-3,5-dione (Formula I) compound, a preparation method therefor, and the use thereof in the treatment and/or the preparation of a drug. The use is to...
|
|
WO/2022/195522A1 |
The present invention relates to a composition comprising at least one active agent that can inhibit anoctamin 6 protein and a method of treating or preventing disease, disorder, or condition associated with virus infection by administer...
|
|
WO/2022/194225A1 |
FXIa inhibitor compound impurities, and a preparation method and use therefor, comprising FXIa inhibitor compound impurity 1, impurity 2, and impurity 4. Also disclosed are a preparation method and use for the impurities. The provided FX...
|
|
WO/2022/194287A1 |
Disclosed are a bicyclic pyridinone compound and the use thereof, and particularly disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/184843A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3a, R3b and R4 are defined in the descri...
|
|
WO/2022/184842A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3 and R4 are defined in the description,...
|
|
WO/2022/174803A1 |
The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to...
|
|
WO/2022/170952A1 |
Provided are a polycyclic pyridazinone derivative serving as an SOS1 inhibitor, a preparation method therefor and use thereof. The structure of the polycyclic pyridazinone derivative is as shown in formula (I), and has a remarkable effec...
|
|
WO/2022/166890A1 |
Substituted pyridazine phenol derivatives and a preparation method therefor, specifically relating to a compound as shown in formula (VI) and a pharmaceutically acceptable salt thereof, which can be used as an NLRP3 inhibitor.
|
|
WO/2022/160637A1 |
A 3-aryl-6-aralkyl-1,4,5,6-tetrahydropyridazine compound, having the structure as shown in formula I. γ, δ-unsaturated N-aryl sulfonyl substituted hydrazone is subjected to a cyclization rearrangement reaction by means of a light and r...
|
|
WO/2022/157686A1 |
The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.
|
|
WO/2022/152852A1 |
This application relates to compounds of Formula (I), which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticar...
|
|
WO/2022/150756A1 |
An improved process for the preparation of high purity Levosimendan includes treatment of Levosimendan crude with an organic acid, adding an organic acid to precipitate Levosimendan and isolating pure Levosimendan from the precipitate. L...
|
|
WO/2022/149618A1 |
The present invention provides a method for producing a compound having alkylated acidic functional groups. The method includes alkylating acidic functional groups by reacting, in a mixture containing a compound having two or more types ...
|
|
WO/2022/149617A1 |
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...
|
|
WO/2022/143695A1 |
The present invention relates to a sulfonamide inhibitor, and a preparation method therefor and an application thereof. Specifically, the compound of the present invention has a structure as represented by formula (I). Also disclosed in ...
|
|
WO/2022/136206A1 |
A Process for the Preparation of N-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-
dihydropyrimidine-5-carboxamide with improved reaction conditions and reduced use of toxic reagents and solvents.
|
|
WO/2022/140309A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, A-oxides, and salts thereof, agricultural compositions containing them and their use as herbicides wherein R1, R2, R3, R4, R14, and X are as defined in the disclosure, A ...
|
|
WO/2022/135567A1 |
A pyridazine-containing compound and a medicinal use thereof. Specifically, a compound represented by formula I or a medicinal salt thereof. The compound or the medicinal salt thereof has an NLRP3 inflammasome inhibiting activity, and ca...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/121517A1 |
Disclosed are a compound as a sodium channel regulator and the use thereof. The compound has obvious inhibition and blocking effects on the activity of the voltage-gated sodium ion channel subtype Nav1.8 ion channel, and can be used as a...
|
|
WO/2022/121868A1 |
A TYK2 inhibitor compound containing an amide group and a heterocycloalkyl group and a preparation method therefor, and the present invention relates to a use thereof in the preparation of a drug for treating or preventing TYK2-related d...
|
|
WO/2022/112493A1 |
The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions c...
|
|
WO/2022/091091A1 |
The present invention relates to polymers comprising bifunctional mono- or polycyclic heterocyclic or heteroaromatic repeating units having disinfecting activity, compositions thereof, and methods for disinfecting surfaces utilizing said...
|
|
WO/2022/090762A1 |
The present invention concerns dispiroindenopyridines and dispiroindenopyridazines and derivatives thereof, methods for their preparation, the study and definition of their properties, and their uses. In particular, the present invention...
|
|
WO/2022/093919A1 |
Disclosed are compounds and their pharmaceutically acceptable salts that possess inhibitory activity against EXO1, and methods of using the compounds and salts to treat cancer and precancerous conditions.
|
|
WO/2022/084334A1 |
The present invention relates to compositions comprising as component (A) at least one compound of formula (I), or an agrochemically acceptable salt thereof wherein R1 is (II) or (III) and, as component (B), at least one compound, or agr...
|
|
WO/2022/083706A1 |
Provided are a series of salts of FXIa inhibitor compounds, pharmaceutical compositions containing said compounds, and a use of said compounds in drugs for the treatment of diseases such as thromboembolism.
|
|
WO/2022/084335A1 |
The present invention relates to compositions comprising as component (A) a compound of formula (I) or an agrochemically acceptable salt thereof wherein R1 is H or methyl; and as component (B) at least one compound, or agrochemically acc...
|
|
WO/2022/083707A1 |
Provided is a pharmaceutical use of an FXIa inhibitor compound or a salt thereof. Specifically, provided is a use of the FXIa inhibitor compound or the salt thereof in preparation of drugs for prevention and/or treatment of arterial and ...
|
|
WO/2022/087141A1 |
The disclosure describes a method of preparing pyridazinone derivatives comprising contacting a compound of formula (I) or a salt thereof: (I) with a compound of formula (II) or a salt thereof: (II) to form a compound of formula (III) or...
|
|
WO/2022/068915A1 |
Provided are a 6-oxo-1,6-dihydropyridazin derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a 6-oxo-1,6-dihydropyridazin derivative as shown by general formu...
|
|
WO/2022/063896A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2022/063876A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2022/058785A1 |
The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib: oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 ol...
|
|
WO/2022/040747A1 |
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...
|
|
WO/2022/037647A1 |
Provided are a crystalline form of a selective NaV inhibitor and a preparation method therefor. Specifically, provided are crystalline forms A to E of the compound 4-((4-(5-chloro-2-(4-fluoro-2-(methoxy-d 3)phenoxy)-4-(trifluoromethyl)be...
|
|
WO/2022/036204A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/032144A1 |
Provided herein are compounds that modulate PRTM5 activity. The compounds may inhibit the binding PRMT5 with a PRMT5 substrate adaptor. The compounds can modulate PRMT5 methyltransferase activity, modulate transcription of a gene regulat...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/026465A1 |
The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating ca...
|
